Risk Factors For Stroke, Myocardial Infarction, or Death Following Carotid Endarterectomy: Results From the International Carotid Stenting Study
Overview
Authors
Affiliations
Objectives: Carotid endarterectomy (CEA) is standard treatment for symptomatic carotid artery stenosis but carries a risk of stroke, myocardial infarction (MI), or death. This study investigated risk factors for these procedural complications occurring within 30 days of endarterectomy in the International Carotid Stenting Study (ICSS).
Methods: Patients with recently symptomatic carotid stenosis >50% were randomly allocated to endarterectomy or stenting. Analysis is reported of patients in ICSS assigned to endarterectomy and limited to those in whom CEA was initiated. The occurrence of stroke, MI, or death within 30 days of the procedure was reported by investigators and adjudicated. Demographic and technical risk factors for these complications were analysed sequentially in a binomial regression analysis and subsequently in a multivariable model.
Results: Eight-hundred and twenty-one patients were included in the analysis. The risk of stroke, MI, or death within 30 days of CEA was 4.0%. The risk was higher in female patients (risk ratio [RR] 1.98, 95% CI 1.02-3.87, p = .05) and with increasing baseline diastolic blood pressure (dBP) (RR 1.30 per +10 mmHg, 95% CI 1.02-1.66, p = .04). Mean baseline dBP, obtained at the time of randomization in the trial, was 78 mmHg (SD 13 mmHg). In a multivariable model, only dBP remained a significant predictor. The risk was not related to the type of surgical reconstruction, anaesthetic technique, or perioperative medication regimen. Patients undergoing CEA stayed a median of 4 days before discharge, and 21.2% of events occurred on or after the day of discharge.
Conclusions: Increasing diastolic blood pressure was the only independent risk factor for stroke, MI, or death following CEA. Cautious attention to blood pressure control following symptoms attributable to carotid stenosis could reduce the risks associated with subsequent CEA.
Phosphodiesterase 4 inhibition as a novel treatment for stroke.
Zhong J, Yu X, Lin Z PeerJ. 2025; 13:e18905.
PMID: 39897494 PMC: 11786714. DOI: 10.7717/peerj.18905.
Tormanen H, Koskinen S, Nuotio K, Vikatmaa P, Kovanen P, Soinne L Eur J Neurol. 2025; 32(1):e16551.
PMID: 39749804 PMC: 11696523. DOI: 10.1111/ene.16551.
Sultan S, Acharya Y, Dulai M, Tawfick W, Hynes N, Wijns W Front Surg. 2024; 11:1361963.
PMID: 38638141 PMC: 11025470. DOI: 10.3389/fsurg.2024.1361963.
Xin W, Yang S, Li Q, Yang X Ann Transl Med. 2021; 9(3):256.
PMID: 33708883 PMC: 7940891. DOI: 10.21037/atm-20-4620.
Howard V, Algra A, Howard G, Bonati L, de Borst G, Bulbulia R Stroke. 2021; 52(2):416-423.
PMID: 33493046 PMC: 9136999. DOI: 10.1161/STROKEAHA.120.030184.